Title
Antimicrobial resistance trends in Methicillin Resistant Staphylococcus aureus (MRSA), India: A in silico analysis
Authors
Manish Purohit* & Ashish Kumar Joshi
Affiliation
Department of Microbiology, MGM Medical College, Indore, India; *Corresponding author
Manish Purohit- E-mail: manishpurohit75@yahoo.co.in
Ashish Kumar Joshi- E-mail: akjoshi2011@gmail.com
Article Type
Research Article
Date
Received September 1, 2026; Revised September 30, 2026; Accepted
September 30, 2026, Published September 30, 2026
Abstract
Methicillin-resistant Staphylococcus aureus infection is a major cause of hospital- and community-acquired infections in India, necessitating continuous institutional surveillance. This retrospective observational study analysed 5,396 non-duplicate clinical isolates (2015–2025), identifying MRSA using cefoxitin disc diffusion and PBP2a confirmation, with susceptibility testing performed per CLSI guidelines. Annual MRSA prevalence ranged from 37.2% to 62.3% (overall 40.5%), with linezolid maintaining consistently high susceptibility (>90%), while ciprofloxacin showed persistently low efficacy (<40%). Clindamycin, gentamicin and co-trimoxazole demonstrated moderate but fluctuating susceptibility trends over time. MRSA remains a sustained institutional burden, highlighting linezolid as the most reliable agent and underscoring the need for continuous antibiogram surveillance and antimicrobial stewardship to guide therapy and curb resistance.
Keywords
Methicillin-resistant Staphylococcus aureus (MRSA), antimicrobial resistance, India, antibiotic susceptibility, hospital acquired infection, tertiary care surveillance
Citation
Purohit & Joshi, Bioinformation 22(9): 6076-6080 (2026)
Edited by
Ritik Kashwani
ISSN
0973-2063
Publisher
License
This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.
